NCT05379348Completed
Davos Alzheimer's Collaborative Study: Sequential Administration of Digital Testing To Screen For Cognitive Impairment Followed By Blood Based Biomarkers To Assist With Timely Detection And Accurate Diagnosis Of Alzheimer's Disease
Source: ClinicalTrials.gov · Last updated 30 Mar 2026
Brief summary (registry, in English)
The purpose of this study is to investigate how we can detect Alzheimer's disease early by using an online memory test and a simple blood test. These new methods for early diagnosis could allow people to begin treatment sooner, with the potential to improve the lives of millions of people.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1423 (actual)
- First submitted
- 13 May 2022
- Start date
- 14 Mar 2022
- Primary completion date
- 5 Aug 2025
- Lead sponsor
- AdventHealth Translational Research Institute
- Diseases
- Alzheimer disease
- NCT number
- NCT05379348
What you commit to
- Study type: Observational
- Participants enrolled: 1423
- From 14 Mar 2022 to the primary completion date, 5 Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior diagnosis of dementia or Alzheimer's disease documented in their medical record and/or as diagnosed by a physician; Exclusion criteria is assessed by by participant's self-reporting of understanding and not having a prior diagnosis of dementia at the time of e-consentand visit 1 at TRI. ).
Other
- Subjects who meet any of the following criteria will not be eligible for entry into the study:
- Subjects who are unable to hear and see well enough to complete the assessments;
Who the study is looking for
- Subjects must meet the following criteria for entry into the study:
- Male or female \> 65 years of age at the time of consent;
- Understand and voluntarily sign an informed consent form;
Age in the registry: 65 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| AdventHealth Translational Research Institute Coordinator of this site? Confirm its status | Orlando | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.